Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE

Date Title and Summary
Toggle Summary Five Prime to Present at 2018 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 25, 2018-- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that it will present two posters during the 2018
Toggle Summary Five Prime Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on May 8
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 24, 2018-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2018 financial results on Tuesday,

Upcoming and Recent Events > MORE